ReviewDiscover oncology2025
Therapeutic positioning of asciminib in chronic myeloid leukemia patients previously treated with multiple tyrosine kinase inhibitors in Qatar.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- FDA-Approved Drugs Containing Amide Functionality in the Last Five Years (2021-2025): Pharmaceutical Use, Trends and Synthetic Approaches.Medicines (Basel, Switzerland) · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic phase-chronic myeloid leukemia (CP-CML) in Qatar presents unique epidemiological and clinical challenges compared with those in the Western population, including nearly half of the affected patients being under 40 years of age. Additionally, the high prevalence of cardiovascular comorbidities in this region significantly influences treatment decisions. This position statement presents an evaluation of the therapeutic role of asciminib in patients previously treated with two or more tyrosine kinase inhibitors and its relevance within Qatar’s healthcare system. Studies have demonstrated asciminib’s superior efficacy in achieving higher rates of major molecular response than bosutinib. Furthermore, compared with ponatinib, asciminib offers a favorable cardiovascular safety profile, making it a preferred option for patients at risk of cardiovascular complications. Cost-effectiveness analyses further support its adoption as a viable treatment alternative in Qatar. Given these considerations, asciminib emerges as a promising therapeutic option for patients with CP-CML requiring third-line treatment, striking a balance between efficacy, safety, and economic feasibility within the local healthcare framework.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.